These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

250 related articles for article (PubMed ID: 18687892)

  • 1. Catalytic organometallic anticancer complexes.
    Dougan SJ; Habtemariam A; McHale SE; Parsons S; Sadler PJ
    Proc Natl Acad Sci U S A; 2008 Aug; 105(33):11628-33. PubMed ID: 18687892
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect of cysteine thiols on the catalytic and anticancer activity of Ru(II) sulfonyl-ethylenediamine complexes.
    Chen F; Romero-Canelón I; Habtemariam A; Song JI; Banerjee S; Clarkson GJ; Song L; Prokes I; Sadler PJ
    Dalton Trans; 2022 Mar; 51(11):4447-4457. PubMed ID: 35226015
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Phenylazo-pyridine and phenylazo-pyrazole chlorido ruthenium(II) arene complexes: arene loss, aquation, and cancer cell cytotoxicity.
    Dougan SJ; Melchart M; Habtemariam A; Parsons S; Sadler PJ
    Inorg Chem; 2006 Dec; 45(26):10882-94. PubMed ID: 17173447
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Organometallic ruthenium anticancer complexes inhibit human glutathione-S-transferase π.
    Lin Y; Huang Y; Zheng W; Wang F; Habtemariam A; Luo Q; Li X; Wu K; Sadler PJ; Xiong S
    J Inorg Biochem; 2013 Nov; 128():77-84. PubMed ID: 23942162
    [TBL] [Abstract][Full Text] [Related]  

  • 5. New cytotoxic and water-soluble bis(2-phenylazopyridine)ruthenium(II) complexes.
    Hotze AC; Bacac M; Velders AH; Jansen BA; Kooijman H; Spek AL; Haasnoot JG; Reedijk J
    J Med Chem; 2003 Apr; 46(9):1743-50. PubMed ID: 12699392
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Tuning the reactivity of osmium(II) and ruthenium(II) arene complexes under physiological conditions.
    Peacock AF; Habtemariam A; Fernández R; Walland V; Fabbiani FP; Parsons S; Aird RE; Jodrell DI; Sadler PJ
    J Am Chem Soc; 2006 Feb; 128(5):1739-48. PubMed ID: 16448150
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Half-sandwich organometallic Ru and Rh complexes of (N,N) donor compounds: effect of ligand methylation on solution speciation and anticancer activity.
    Mészáros JP; Pape VFS; Szakács G; Németi G; Dénes M; Holczbauer T; May NV; Enyedy ÉA
    Dalton Trans; 2021 Jun; 50(23):8218-8231. PubMed ID: 34032247
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Structure-activity relationships for organometallic osmium arene phenylazopyridine complexes with potent anticancer activity.
    Fu Y; Habtemariam A; Basri AM; Braddick D; Clarkson GJ; Sadler PJ
    Dalton Trans; 2011 Oct; 40(40):10553-62. PubMed ID: 21860862
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Inhibition of cancer cell growth by ruthenium(II) arene complexes.
    Morris RE; Aird RE; Murdoch Pdel S; Chen H; Cummings J; Hughes ND; Parsons S; Parkin A; Boyd G; Jodrell DI; Sadler PJ
    J Med Chem; 2001 Oct; 44(22):3616-21. PubMed ID: 11606126
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pyrene-based fluorescent Ru(II)-arene complexes for significant biological applications: catalytic potential, DNA/protein binding, two photon cell imaging and
    Pragti ; Kundu BK; Upadhyay SN; Sinha N; Ganguly R; Grabchev I; Pakhira S; Mukhopadhyay S
    Dalton Trans; 2022 Mar; 51(10):3937-3953. PubMed ID: 35171173
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Structure-activity relationships for osmium(II) arene phenylazopyridine anticancer complexes functionalised with alkoxy and glycolic substituents.
    Needham RJ; Bridgewater HE; Romero-Canelón I; Habtemariam A; Clarkson GJ; Sadler PJ
    J Inorg Biochem; 2020 Sep; 210():111154. PubMed ID: 32771772
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Highly cytotoxic trithiophenolatodiruthenium complexes of the type [(η6-p-MeC6H4Pri)2Ru2(SC6H4-p-X)3]+: synthesis, molecular structure, electrochemistry, cytotoxicity, and glutathione oxidation potential.
    Giannini F; Furrer J; Ibao AF; Süss-Fink G; Therrien B; Zava O; Baquie M; Dyson PJ; Stěpnička P
    J Biol Inorg Chem; 2012 Aug; 17(6):951-60. PubMed ID: 22707191
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cytotoxicity of half sandwich ruthenium(II) complexes with strong hydrogen bond acceptor ligands and their mechanism of action.
    Das S; Sinha S; Britto R; Somasundaram K; Samuelson AG
    J Inorg Biochem; 2010 Feb; 104(2):93-104. PubMed ID: 19913918
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Maltol-derived ruthenium-cymene complexes with tumor inhibiting properties: the impact of ligand-metal bond stability on anticancer activity in vitro.
    Kandioller W; Hartinger CG; Nazarov AA; Bartel C; Skocic M; Jakupec MA; Arion VB; Keppler BK
    Chemistry; 2009 Nov; 15(45):12283-91. PubMed ID: 19821465
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Tuning the hydrolytic aqueous chemistry of osmium arene complexes with N,O-chelating ligands to achieve cancer cell cytotoxicity.
    Peacock AF; Parsons S; Sadler PJ
    J Am Chem Soc; 2007 Mar; 129(11):3348-57. PubMed ID: 17319668
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Synthesis, characterization and biological evaluation of novel Ru(II)-arene complexes containing intercalating ligands.
    Nikolić S; Rangasamy L; Gligorijević N; Aranđelović S; Radulović S; Gasser G; Grgurić-Šipka S
    J Inorg Biochem; 2016 Jul; 160():156-65. PubMed ID: 26818702
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Ferrocenoyl pyridine arene ruthenium complexes with anticancer properties: synthesis, structure, electrochemistry, and cytotoxicity.
    Auzias M; Therrien B; Süss-Fink G; Stepnicka P; Ang WH; Dyson PJ
    Inorg Chem; 2008 Jan; 47(2):578-83. PubMed ID: 18085776
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Design of Ru-arene Complexes for Antitumor Drugs.
    Su W; Li Y; Li P
    Mini Rev Med Chem; 2018; 18(2):184-193. PubMed ID: 28494728
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Catalysis of regioselective reduction of NAD+ by ruthenium(II) arene complexes under biologically relevant conditions.
    Yan YK; Melchart M; Habtemariam A; Peacock AF; Sadler PJ
    J Biol Inorg Chem; 2006 Jun; 11(4):483-8. PubMed ID: 16604356
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Structure-activity relationships for cytotoxic ruthenium(II) arene complexes containing N,N-, N,O-, and O,O-chelating ligands.
    Habtemariam A; Melchart M; Fernandez R; Parsons S; Oswald ID; Parkin A; Fabbiani FP; Davidson JE; Dawson A; Aird RE; Jodrell DI; Sadler PJ
    J Med Chem; 2006 Nov; 49(23):6858-68. PubMed ID: 17154516
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.